Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 13/20 | 0.77 |
| ▸ | CPT1B | Q92523 | 13/20 | 0.77 |
| ▸ | CPT2 | P23786 | 12/20 | 0.77 |
| ▸ | RORC | P51449 | 5/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | RORA | P35398 | 1/20 | 0.56 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.56 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.56 |
| ▸ | RORB | Q92753 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30015474 | 1.00 | CPT1A (0.77) | CPT1ACPT1BCPT2RORCNR1I2 | |
| SCHEMBL30015215 | 0.95 | CPT1A (0.85) | CPT1ACPT1BCPT2RORCLMNA | |
| SCHEMBL3571679 | 0.95 | CPT1A (0.85) | CPT1ACPT1BCPT2RORCLMNA | |
| SCHEMBL30015584 | 0.92 | CPT1A (0.90) | CPT1ACPT1BCPT2RORCNR1I2 | |
| SCHEMBL3575974 | 0.92 | CPT1A (0.90) | CPT1ACPT1BCPT2RORCNR1I2 | |
| SCHEMBL3573999 | 0.91 | CPT1A (0.66) | CPT1ACPT1BCPT2RORCNR1I2 | |
| SCHEMBL3582331 | 0.90 | CPT1A (0.90) | CPT1ACPT1BCPT2RORCNR1I2 | |
| SCHEMBL30015360 | 0.90 | CPT1A (0.90) | CPT1ACPT1BCPT2RORCNR1I2 | |
| SCHEMBL3572927 | 0.90 | CPT1A (0.76) | CPT1ACPT1BCPT2MAPT | |
| SCHEMBL30015618 | 0.90 | CPT1A (0.76) | CPT1ACPT1BCPT2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1926711-B1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | claimed |
| US-7713996-B2 | Indolyl derivatives which are L-CPT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-05-11 | — | — | US | claimed |
| EP-1926711-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-04 | — | — | EP | claimed |
| WO-2007031429-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | WO | claimed |
| US-20070060567-A1 | Novel indolyl derivatives which are L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-03-15 | — | — | US | claimed |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2022212568-A9 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | 1BASE PHARMACEUTICALS, LLC (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-1926711-B1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | disclosed |
| US-7713996-B2 | Indolyl derivatives which are L-CPT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1926711-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007031429-A1 | NOVEL HETEROBICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF LIVER CARNITINE PALMITOYL TRANSFERASE | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| US-20070060567-A1 | Novel indolyl derivatives which are L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060567-A1 | Novel indolyl derivatives which are L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | CPT1A 1/4885CPT1B 2/4885CPT2 3/4885 |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | CPT2, PC, SREBF2 | CPT1A 15/4885CPT1B 50/4885CPT2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.